HHS Breaks with FDA Scientists on 503A Peptide Compounding
Despite the FDA’s stated views at the compounding advisory committee meeting in July 2026 (here) regarding the safety and or efficacy of the proposed peptides, HHS today announced an “enforcement discretion policy regarding the use of certain peptide bulk drug substances in compounding while the list of bulk drug substances that can be used in […]

